Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that plays a pivotal role in accelerating the development of groundbreaking therapeutic candidates. With an extensive portfolio of over 70 assets, XOMA acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies. This unique model enables XOMA to provide non-dilutive, non-recourse funding to its partners, helping them advance their internal drug candidates or cater to general corporate needs.
Notably, XOMA has pioneered in the discovery and development of antibody therapeutics, leading to over 20 licenses producing milestone and royalty payments in the future. One key asset in their portfolio is X358, an allosteric monoclonal antibody aimed at treating hyperinsulinism by reducing insulin receptor activity.
XOMA has recently expanded its portfolio through strategic acquisitions. In January 2024, the company acquired an economic interest in DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc., for $8 million. DSUVIA® is an FDA-approved pain management option used in supervised medical settings. The agreement stipulates that XOMA will receive all royalties and milestones related to DSUVIA® until $20 million is accrued. Subsequently, royalties will be shared between XOMA and Talphera.
Further broadening its portfolio, XOMA acquired Kinnate Biopharma in April 2024, bringing additional assets into their royalty pipeline. Kinnate’s lead candidates include investigational pan-RAF inhibitor exarafenib and FGFR inhibitor KIN-3248, both targeting cancers with specific genetic alterations.
In April 2024, XOMA announced a $9 million milestone following the FDA approval of Day One Biopharmaceuticals’ OJEMDA™ (tovorafenib), designed to treat pediatric low-grade glioma harboring BRAF alterations. This approval marks a significant addition to XOMA's cash flow and royalty income.
Additionally, XOMA's economic interest in three of Daré Bioscience's women's health products, including the FDA-approved XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream, 3.6%, signifies their commitment to addressing underrepresented therapeutic areas with significant growth potential.
As of their latest financial results, XOMA reported strong cash reserves and a growing portfolio of commercial and development-phase assets, ensuring long-term sustainability and value creation for shareholders. The company’s disciplined approach to capital deployment and strategic acquisitions highlights its commitment to enhancing human health through biotechnology advancements.
XOMA Corporation announced cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Preferred Stock will receive $0.53906 per share, while holders of the 8.375% Series B Cumulative Preferred Stock will receive $0.52344 per depositary share. These dividends will be paid on January 18, 2022, to shareholders of record as of January 4, 2022. XOMA continues to play a unique role in biotechnology by acquiring future economic rights to therapeutic candidates, supporting funding for developers.
XOMA Corporation (Nasdaq: XOMA) announced that CEO Jim Neal will present at two upcoming investor conferences. The first is the Biotech Showcase 2022, taking place virtually from January 10-12 and January 17-19, 2022, where Neal will participate in a fireside chat titled, “Royalty Licenses: An Economic Asset Often Ignored” on January 10 at 10:30 AM PT. The second conference is the H.C. Wainwright BioConnect Virtual Conference, held January 10-13, 2022, with a presentation available on-demand starting January 10 at 4:00 AM PT.
XOMA Corporation has appointed Jim Neal as Chairman of the Board, who will continue in his role until a new CEO is selected. Former Chairman, W. Denman Van Ness, will serve as Lead Independent Director. XOMA's portfolio includes over 70 assets in various stages of development, with significant recent milestones, including a $35 million payment from Novartis for advancing a candidate to Phase 3. XOMA maintains a debt-free balance sheet and expects to have nearly $100 million in cash following the Novartis milestone, positioning the company for continued growth.
XOMA Corporation (Nasdaq: XOMA) has announced a significant development as NIS793, an anti-TGFβ monoclonal antibody, progresses to Phase 3 trials, triggering a $35 million milestone payment from Novartis. The trial aims to evaluate NIS793's efficacy and safety in treating first-line metastatic pancreatic ductal adenocarcinoma. NIS793 has also received Orphan Drug Designation from the FDA. This milestone is part of a potential $410 million in milestone payments from Novartis, with tiered royalties on future sales based on successful commercialization.
XOMA Corporation reported Q3 2021 financial results, noting total revenues of $0.9 million, a rise from $0.6 million in Q3 2020. A $0.5 million milestone was earned from Compugen after AstraZeneca dosed the first patient in a study of AZD2936. R&D expenses were $30,000, while G&A expenses increased to $4.3 million. The net loss expanded to $4.4 million from $1.1 million a year earlier. XOMA held $68.8 million in cash at quarter-end, down from $84.2 million at the end of 2020, yet confident it can fund operations for multiple years.
XOMA Corporation (NASDAQ: XOMA) announced that CEO Jim Neal will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 28, 2021, at 10:20 AM PT. As a biotechnology royalty aggregator, XOMA plays a crucial role in advancing health by acquiring future economics from pre-commercial therapies, providing non-dilutive funding for biotech companies. The company manages over 70 assets linked to therapeutic candidates, enhancing its portfolio and potential revenue streams. Visit www.xoma.com for more details.
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its preferred stockholders. The holders of the 8.625% Series A Cumulative Perpetual Preferred Stock will receive a dividend of $0.53906 per share. Holders of the 8.375% Series B Cumulative Perpetual Preferred Stock will receive $0.52344 per depositary share. These dividends will be paid on or about October 15, 2021, to shareholders on record as of October 1, 2021.
XOMA Corporation announced that CEO Jim Neal will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. The presentation will be available on demand starting September 13, 2021, at 7:00 AM ET. Interested parties can access it through the link or via XOMA's investor relations section. A replay will be available for 90 days.
XOMA Corporation (NASDAQ: XOMA) has appointed Heather L. Franklin, President and CEO of Blaze Bioscience, to its Board of Directors. With over 20 years in biotechnology, Franklin brings extensive experience in corporate development and strategy. She is recognized for negotiating significant deals, including a notable $1.1 billion collaboration with Bristol Myers Squibb. XOMA aims to enhance its royalty aggregator model by leveraging Franklin’s expertise in licensing and transactions to grow its portfolio of royalty assets.
XOMA Corporation announced its Q2 2021 financial results, reporting total revenues of $0.9 million, up from $0.4 million in Q2 2020, driven by a $0.5 million milestone from Janssen. Operating cash at quarter-end was $78.9 million, with no outstanding debt. The company raised $40 million through a preferred stock offering. Noteworthy developments include Orphan Drug Designation for NIS793 in pancreatic cancer and Rare Pediatric Disease Designation for DAY101. Despite a net loss of $2.2 million, XOMA's strong balance sheet supports future growth.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
What does XOMA Corporation do?
What is XOMA’s business model?
What recent acquisitions has XOMA made?
What are some key assets in XOMA's portfolio?
How does XOMA generate revenue?
What is the significance of XOMA’s investment in X358?
How does XOMA support biotech companies?
What was the financial impact of XOMA’s acquisition of DSUVIA®?
Who are some of XOMA’s partners?
What are XOMA's future plans for growth?
